News Releases

Press Releases

  • 4/3/18 10:38 am EDT
    PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at The MicroCap Conference on Monday, April 9th at 1:00 p.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss the Company’s innovative business model and review PAVmed’s lead products. The conference will be held April 9th and 10th at the Essex House in New Yorkmore...
  • 3/16/18 4:05 pm EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that its previously disclosed offer to exchange Series W Warrants (Nasdaq: PAVMW, the “W Warrant”) for Series Z Warrants (the “Offer”) has been extended, in accordance with applicable rules and regulations governing tender offers, until 5:00 P.M., Eastern Time, on April 2, 2018, unless further extended or terminated.more...
  • 3/14/18 10:33 am EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss the Company’s innovative business model and review PAVmed’s lead products.more...
  • 2/21/18 7:30 am EST

    Warrant Exchange Offer to Extend Until March 19, 2018

    New Warrants to be Identical to Those Issuable in Recently Announced Rights Offering

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced the filing of a warrant exchange offer (the “Warrant Offer”) with the U.S. Securities and Exchange Commission (the “SEC”) providing holders of the Company’s outstanding Series W Warrants (Nasdaq: PAVMW, the “W Warrant”) the right to exchange every two W Warrants for one Series Z Warrant (the “Z Warrantmore...
  • 2/12/18 7:30 am EST

    New Warrants to be Identical to Those Issuable in Recently Announced Rights Offering

    Exchange Designed to Streamline Capital Structure

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced it intends to file exchange offer materials (the “Exchange”) providing the holders of the Company’s outstanding Series W Warrants (Nasdaq: PAVMW, the “W Warrant”) with the opportunity to exchange 2 W Warrants for 1 Series Z Warrant (the “Z Warrant”). Each of the Company’s outstanding W Warrants is currentlymore...
  • 2/9/18 4:30 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced the completion of its previously announced offer to exercise its publicly-traded warrants (the “Series W Warrants”) at a temporarily reduced exercise price of $2.00 per share. The offer expired at 11:59 P.M. (Eastern Time) on February 8, 2018. As of the expiration date, 34,345 Series W Warrants had been tenderedmore...
  • 1/25/18 4:00 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it has completed the sale of 234,540 shares (“Option Shares”) of common stock, $0.001 par value per share (“Common Stock”), in connection with the partial exercise of the over-allotment option granted to the underwriter in its previously announced public offering of 2,415,278 shares of Common Stock (“Firm Sharesmore...
  • 1/23/18 4:00 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced the closing of its previously announced underwritten public offering of 2,415,278 shares of its common stock at a public offering price of $1.80 per share. Dawson James Securities, Inc. acted as sole underwriter of the offering. Net proceeds from the sale by PAVmed of the shares after underwritingmore...
  • 1/19/18 8:25 am EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced the pricing of its previously announced underwritten public offering of 2,415,278 shares of its common stock at a price to the public of $1.80 per share. In addition, PAVmed has granted the underwriters of the offering a 45-day option to purchase up to 362,292 additional shares of its common stock to cover overallotments,more...
  • 1/18/18 5:56 pm EST
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it intends to offer shares of common stock in an underwritten public offering. PAVmed also expects to grant to the underwriters a 45-day option to purchase additional shares of common stock to cover overallotments, if any. PAVmed intends to use the net proceeds from this offering for working capital and other generalmore...

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here to view the Annual Report for PAVmed Inc 2017 Annual Meeting